Your selection
Innovation / 02.10.2024
Eckert & Ziegler: Spin-off of Pentixapharm AG Registered with the Commercial Register
Berlin, 2 October 2024.
Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) announces that the spin-off resolution approved at the Annual General Meeting on 26 June 2024 was entered in the commercial register of the Charlottenburg (Berlin) District Court today. With the entry in the commercial register of Eckert & Ziegler SE, the spin-off of Pentixapharm AG became legally effective. All shares in Pentixapharm AG held by Eckert & Ziegler have thus been legally transferred from Eckert & Ziegler SE to Pentixapharm Holding AG.
In compensation, the shareholders of Eckert & Ziegler SE will receive Pentixapharm Holding AG shares at a ratio of 1:1. The number of Eckert & Ziegler shares held by each Eckert & Ziegler shareholder after the close of trading today, taking into account any outstanding stock market transactions, will determine their entitlement. All Pentixapharm Holding AG shares created as part of the spin-off are expected to be admitted to the Regulated Market of the Frankfurt Stock Exchange in the Prime Standard segment on 2 October 2024.
Initial trading of the Pentixapharm Holding AG shares is scheduled for 3 October 2024. On the same day, the listing of the Eckert & Ziegler SE shares ‘ex spin-off’ is planned. The deposit-side posting of the Pentixapharm Holding shares to the securities accounts of Eckert & Ziegler shareholders is expected to take place on 7 October 2024.
Further information on the IPO of Pentixapharm AG can be found here: www.pentixapharm.com
About Eckert & Ziegler.
Eckert & Ziegler SE with more than 1.000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.
Overview News
News Buch Berlin
Eckert & Ziegler Achieves Further Earnings Growth and Double-Digit Sales Growth in the Medical Segment
Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) increased sales in the first nine months of 2025 by 4% to €224.1 million compared to the same period last year. EBIT before special items from continuin...
more ...T-knife Therapeutics Presents Preclinical Data on PRAME-Targeted TK-6302 Highlighting its Potential as a Promising, Category-leading Therapy
Comprehensive TK-6302 data demonstrate preclinical efficacy and safety, supporting clinical readiness, alongside established scalable manufacturing. TK-6302 Clinical Trial Application planned in Q4 20...
more ...Why APOE4 raises Alzheimer’s risk
Researchers at the Max Delbrück Center and Aarhus University have found a mechanism through which the gene variant APOE4, long linked to a high risk of developing Alzheimer’s disease, impairs neuronal...
more ...Events Buch Berlin
16.12.2025, 15:30
Weihnachtliche Führung durch die einzigartige Sammlung historischer Mikroskope auf dem Campus Berlin-Buch
Lernen Sie die Anfänge der Berliner Mikroskop-Produktion und ihren Einfluss auf die moderne Biomedizin kennen - unter anderem auf die medizinische Forschung in Berlin-Buch!
more ...16.12.2025, 16:30
Invitation: Christmas tour of the unique collection of historical microscopes on the Campus Berlin-Buch
Discover the beginnings of Berlin’s microscope production and its influence on modern biomedicine. Neuroscientist Prof. Dr. Helmut Kettenmann will guide you through the microscope exhibition at the Ma...
more ...06.01.2026, 16:00
Vorlesung und Lehrerfortbildung: "Wenn das Immunsystem das Gehirn angreift – Autoimmunerkrankungen des zentralen Nervensystems"
Vorlesungsreihe: Neue Wege in der Biomedizin: Aktuelle Forschungsthemen vom Campus Berlin-Buch. Für Lehrkräfte, Schülerinnen und Schüler sowie Interessierte.
more ...
